ArticleInternational archives of allergy and immunology2026
Erratum.
Article in International archives of allergy and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum for
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the article "Safety and Efficacy of Remibrutinib for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis" [Int Arch Allergy Immunol. 2026;187(6):635-646. https://doi.org/10.1159/000548302] by Muhammad Burhan et al., online supplementary Figure 11 has been corrected.Following publication, the authors reviewed their data and found that an error occurred during the compilation of their forest plot of online supplementary Figure 11. This error arose from an internal data entry oversight during the analysis phase.The corrected online supplementary Figure 11 has been provided here. In addition, the corrected Results sentence in the manuscript text is as follows:"Three studies examined nasopharyngitis cases in both groups. The pooled analysis, as depicted in online supplementary Figure 11, demonstrated a statistically significant increase in the risk of nasopharyngitis in the remibrutinib group compared with placebo (RR: 1.88, 95% CI: 1.11-3.19, I² = 0%, p = 0.02)."
Identifiers
42804412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.